Peptide Based Infection Therapeutics Sales Surge through E-commerce: Study

Surging chronic diseases to spur the production of peptide based infection drugs facilitating the growth to the market

Fact.MR, Rockville MD: High investments in research and development will be a strong focus area for peptide based infection drugs manufacturers in 2021 and beyond, according to the latest edition of the report on peptide based infection therapeutics market by consulting firm Fact.MR. According to the study, the market to exhibit robust growth by 2022 with a valuation less than US$ 1.5 Bn.

According to the study, higher investment in the healthcare sector, owing to the increased demand for the peptide based infection drugs in the treatment of chronic diseases such as cardiovascular disease, cancer and diabetes has to growing importance of peptide based infection therapeutics market. Also, emerging biotech and pharmaceutical companies coupled with advanced pipeline projects are bolstering the demand for the peptide based infection therapeutic market.

For instance, according to the Centre for Disease Control and Prevention, in 2018 about 75% from the peptide drugs in the market gained global sales over US$ 1 billion for the use in cancer treatment such as leuprolide and octreotide peptides. Acknowledging this study, healthcare providers have incorporated numerous advanced therapeutic treatment approaches, thus stimulating the growth.

“Precipitous advancements in application of healthcare industry and rapid technological advancements to witness a breakthrough in the forecast period owing to the higher production of peptide based infection drugs,” says the Fact.MR analyst.

Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=188

Key Takeaways

  • Online pharmacies to acquire surging popularity in North America, attributed to its ease in availability
  • North America is poised to prevail over other regions through 2021
  • Asia Pacific excluding Japan will be the most lucrative markets globally, growing at 8.7% CAGR
  • By drug type, boceprevir to surpass telaprevir as a dominant segment post 2022, at 8.2% CAGR
  • Hospital pharmacies to strive against retail pharmacies for higher growth by 2022-end
  • Latin America and MEA expected to remain sluggish through 2022

Prominent Drivers

  • Higher investment in healthcare industry and advancement in technologies will spur growth
  • Rising prevalence of infectious diseases such as hepatitis C and genotype 1, fostering telaprevir sales, to bolster peptide based infection therapeutic growth
  • Increased usage in biotech and pharmaceutical companies to create growth opportunities
  • Therapeutic application of peptides in treatment of chronic diseases such as cancer and diabetes to boost the demand

Key Restraints

  • Peptide hydrophilicity responsible for its poor permeability through physiological barriers to restrain the growth
  • Eventual risk of immunogenic effects and high cost production to hamper sales

Discover more about the peptide based infection therapeutics market with 42 figures, 140 data tables and the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/188/peptide based infection therapeutics-market

Competitive Landscape

Vertex Pharmaceuticals Incorporated, Merck & Co. Inc., and Parchem Fine and Speciality Chemicals are some of the key players profiled by Fact.MR. Key players are adopting numerous organic and inorganic strategies such as product launches, collaborations, M&A’s, to strengthen their position in the market.

Recently, in January 2021, Merck announced the FDA approval for VERQUVO, its first soluble guanylate cyclase stimulator to treat heart failure. It is the first stimulator that is needed for intravenous diuretics in adults with symptomatic heart failure.

Also, in 2019, Merck announced that it has acquired Tilos Therapeutics and agreed for a definitive agreement targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases produced by the biopharmaceutical company developing therapeutics.

More Insights on the Peptide based infection therapeutics Market

Fact.MR presents an in-depth analysis on the global Peptide based infection therapeutics market. The report divulges essential insights on peptide based infection therapeutics market on the basis of drug type (telaprevir, and boceprevir), distribution channel (hospital pharmacies, retail pharmacies and online pharmacies), and regions (North America, Latin America, Europe, Japan, APEJ, and Middle East and Africa)

Request more information about Report Methodology

https://www.factmr.com/connectus/sample?flag=RM&rep_id=188

Explore Fact.MR’s Coverage on the Healthcare Domain

 Peptide Based Cancer Therapeutics Market: A recent study by Fact.MR on the peptide based cancer therapeutics market offers an unbiased analysis on the opportunities and challenges for the forecast period. The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders and emerging players.

 Peptide Based Metabolic Disorders Market: A detailed assessment of peptide based metabolic disorders value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the peptide based metabolic disorders market along with their product portfolios enhances the reliability of this comprehensive research study.  

 Peptide Based Gastrointestinal Disorders Market: The global peptide based gastrointestinal disorder therapeutics market report by Fact.MR delivers a detailed analysis on the strategies and competitive landscape for the upcoming period. The key players’ market share data provided by the report given you a detailed insights on the shortcomings and forthcomings of the market for the forecast period. 

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.    

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Source: Fact.MR

Back to news